stockrowCollegium Pharmaceutical, Inc.
COLL Healthcare Drug Manufacturers Specialty & Generic
Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024.
- Revenue
- +3.33%
- EPS
- −31.0%
- Free cash flow
- +10.2%
- Total debt
- +33.8%
Quarter to September 2026, against a year earlier
Follow COLL
Alert me
Collegium Pharmaceutical, Inc. (COLL) P/E ratio
As of 5 November 2026, Collegium Pharmaceutical, Inc. (COLL) trades at a P/E ratio of 20.5×. Over the past ten years it has ranged from 0.0× (September 2023) to 114× (December 2023); the current reading is higher than 84% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 23.2× | 72.92% |
| FY2024 | 13.4× | (36.98%) |
| FY2023 | 21.2× | — |
| FY2022 | 0.0× | — |
| FY2021 | 9.3× | (64.27%) |
| FY2020 | 26.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 17.9× | (24.41%) |
| Jun 2026 | 23.7× | 69.56% |
| Mar 2026 | 14.0× | (39.73%) |
| Dec 2025 | 23.2× | 22.40% |
| 37 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TKNO Alpha Teknova, Inc. compare | n/m |
| HROW Harrow, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| EOLS Evolus, Inc. compare | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 4.3× |
| AMPH Amphastar Pharmaceuticals, Inc. compare | 12.3× |
| COLL Collegium Pharmaceutical, Inc. | 20.5× |
| CRON Cronos Group Inc. compare | 21.9× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)